High prevalence of psychotropic drug use among persons with and without Alzheimer[U+05F3]s disease in Finnish nationwide cohort

European Neuropsychopharmacology

Volumn 24, Issue 11, 2014, Pages 1729-1737

  Taipale, Heidi ^a   Koponen, Marjaana ^a   Tanskanen, Antti ^b,c   Tolppanen, Anna Maija ^a   Tiihonen, Jari ^a,b   Hartikainen, Sirpa ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Alzheimer U+05F3 s disease; Older persons; Psychotropic drugs

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROTHIXENE; CITALOPRAM; CLOZAPINE; DIXYRAZINE; ESCITALOPRAM; HALOPERIDOL; LORAZEPAM; MELPERONE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PALIPERIDONE; PERPHENAZINE; PRESCRIPTION DRUG; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PREVALENCE; PSYCHIATRIST; REIMBURSEMENT; CASE CONTROL STUDY; DRUG UTILIZATION; FINLAND; MENTAL DISORDERS; MIDDLE AGED; REGISTER; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PSYCHOTROPIC DRUGS; REGISTRIES;

EID: 84918840159     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.10.004     Document Type: Article

References (36)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Ballard C., Hanney M.L., Theodoulou M., Douglas S., McShane R., Kossakowski K., Gill R., Juszczak E., Yu L.M., Jacoby R. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009, 8:151-157.
3. Byerly M.J., Weber M.T., Deean L.B., Snow L.R., Worley M.A., Lescouflair E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001, 18:45-61.
4. Coupland C., Dhiman P., Morriss R., Arthur A., Barton G., Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Br. Med. J. 2011, 343:d4551.
5. Cumming R.G., Le Couteur D.G. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003, 17:825-837.
6. EMA-European Medicines Agency, 2008. CHMP assessment report on conventional antipsychotics. Procedure under Article 5(3) of Regulation (EC) No. 726/2004. Available at . http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500054057.pdf.
7. FDA - U.S. Food and Drug Administration, 2005. Public health advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at (accessed 08.04.14.). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm.
8. FDA - U.S. Food and Drug Administration, 2008. Postmarketing drug safety for patients and providers. Information on conventional antipsychotics. Available at (accessed 08.04.14.). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107211.htm.
9. Finnish Medical Society Duodecim, Helsinki, 2010. Current care: memory disorders. [in Finnish with English summary]. Available at (accessed 10.04.14.). http://www.kaypahoito.fi.
10. Franchi C., Tettamanti M., Marengoni A., Bonometti F., Pasina L., Cortesi L., Fortino I., Bortolotti A., Merlino L., Lucca U., Riva E., Nobili A. Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur. Neuropsychopharmacol. 2012, 22:569-577.
11. Gardette V., Lapeyre-Mestre M., Coley N., Cantet C., Montastruc J.L., Vellas B., Andrieu S. Antipsychotic use and mortality risk in community-dwelling Alzheimer[U+05F3]s disease patients: evidence for a role of dementia severity. Curr. Alzheimer Res. 2012, 9:1106-1116.
12. Gerhard T., Huybrechts K., Olfson M., Schneeweiss S., Bobo W.V., Doraiswamy P.M., Devanand D.P., Lucas J.A., Huang C., Malka E.S., Levin R., Crystal S. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br. J. Psychiatry 2014, 205:44-51.
13. Gill S.S., Bronskill S.E., Normand S-L., Anderson G.M., Sykora K., Lam K., Bell C.M., Lee P.E., Hadas D.F., Herrmann N., Gurwitz J.H., Rochon P.A. Antipsychotic drug use and mortality in older adults with dementia. Ann of Intern. Med. 2007, 146:775-786.
14. Gisev N., Hartikainen S., Chen T.F., Korhonen M., Bell J.S. Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study. Can. J. Psychiatry 2011, 56:377-381.
15. Guthrie B., Clark S.A., McCowan C. The burden of psychotropic drug prescribing in people with dementia: a population database study. Age Ageing 2010, 39:637-642.
16. Hanlon J.T., Horner R.D., Schmader K.E., Fillenbaum G.G., Lewis I.K., Wall W.E., Landerman L.R., Pieper C.F., Blazer D.G., Cohen H.J. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin. Pharmacol. Ther. 1998, 64:684-692.
17. Hartikainen S., Lönnroos E., Louhivuori K. Medication as a risk factor for falls: critical systematic review. J. Gerontol. Med. Sci. 2007, 62A:1172-1181.
18. Kales H.C., Kim H.M., Zivin K., Valenstein M., Seyfried L.S., Chiang C., Cunningham F., Schneider L.S., Blow F.C. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 2012, 169:71-79.
19. Kripke D.F., Klauber M.R., Wingard D.L., Fell R.L., Assmus J.D., Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol. Psychiatry 1998, 43:687-693.
20. Lopez O.L., Becker J.T., Chang Y.F., Sweet R.A., Aizenstein H., Snitz B., Saxton J., McDade E., Kamboh M.I., DeKosky S.T., Reynolds C.F., Klunk W.E. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer[U+05F3]s disease. Am. J. Psychiatry 2013, 170:1051-1058.
21. Martinez C., Jones R.W., Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer[U+05F3]s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open 2013, 7:3.
22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer[U+05F3]s disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer[U+05F3]s disease. Neurology 1984, 34:939-944.
23. Mittal V., Kurup L., Williamson D., Muralee S., Tampi R.R. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am. J. Alzheimers Dis. Other Dement. 2011, 26:10-28.
24. Oderda L.H., Young J.R., Asche C.V., Pepper G.A. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann. Pharmacother. 2012, 46:917-928.
25. Paterniti S., Dufouil C., Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J. Clin. Psychopharmacol. 2002, 22:285-293.
26. Rattinger G.B., Burcu M., Dutcher S.K., Chhabra P.T., Rosenberg P.B., Simoni-Wastila L., Franey C.S., Walker L.D., Zuckerman I.H. Pharmacotherapeutic management of dementia across settings of care. J. Am. Geriatr. Soc. 2013, 61:723-733.
27. Rhee Y.J., Csernansky J.G., Emanuel L.L., Chang C.G., Shega J.W. Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia. J. Am. Geriatr. Soc. 2011, 59:2100-2107.
28. Ried L.D., Jia H., Feng H., Cameon R., Wang X., Tueth M., Wu S.S. Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality. Ann. Pharmacother. 2011, 45:888-897.
29. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., Wang P.S. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can. Med. Assoc. J. 2007, 176:627-632.
30. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J. Am. Med. Assoc. 2005, 294:1934-1943.
31. Schulze J., Glaeske G., van den Bussche H., Kaduszkiewicz H., Koller D., Wiese B., Hoffmann F. Prescribing of antipsychotic drugs in patients with dementia: a comparison with age-matched and sex-matched non-demented controls. Pharmacoepidemiol. Drug Saf. 2013, 22:1308-1316.
32. Schulze J., van den Bussche H., Glaeske G., Kaduszkiewicz H., Wiese B., Hoffmann F. Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. Eur. Neuropsychopharmacol. 2013, 23:1034-1042.
33. Tolppanen A.M., Taipale H., Koponen M., Lavikainen P., Tanskanen A., Tiihonen J., Hartikainen S. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer[U+05F3]s disease research - the Medication use among persons with Alzheimer[U+05F3]s disease (MEDALZ-2005) study. Clin. Epidemiol. 2013, 5:277-285.
34. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., Brookhart M.A. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 2005, 353:2335-2341.
35. WHO Collaborating Centre for Drug Statistics Methodology, 2014. The Anatomical Therapeutic Chemical Classification System. (accessed 10.04.14.). http://www.whocc.no/atc_ddd_index/.
36. Xing D., Ma X.L., Wang J., Yang Y., Chen Y. Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos. Int. 2014, 25:105-120.